Johnson & Johnson Services, Inc., GlaxoSmithKline Plc and Taisho Pharmaceutical Holdings Co., Ltd. are Dominating in the Global Alopecia Treatment (Hair Loss) Market in 2019

Global Alopecia Treatment (Hair Loss) Market is expected to grow with the CAGR of 6.0% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-alopecia-treatment-hair-loss-market

Global alopecia treatment (hair loss) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global alopecia treatment (hair loss) market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the alopecia treatment (hair loss) market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical. The company has taken this decision in order to enhance the sales of Rogaine, a hair loss treatment containing minoxidil. Rogaine is a FDA approved alopecia treatment and is one of the top selling hair loss treatment brands. This initiative has helped the company to enhance the company’s overall revenue.

Johnson & Johnson Services, Inc. is the dominating player in global alopecia treatment (hair loss) market. The other key players existing in the alopecia treatment (hair loss) market are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB,  HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (a subsidiary of Endo International plc), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Aurobindo Pharma, Perrigo Company plc, Viviscal Limited (a subsidiary of Church & Dwight Co., Inc.), Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech among others.

Alopecia Treatment (Hair Loss) MarketJohnson & Johnson Services, Inc.:

Johnson & Johnson Services, Inc. is headquartered in New Jersey, U.S. and was founded in 1886. The company is focused on improving access and affordability, create healthier communities and put a healthy mind, body and environment within reach of everyone, everywhere. The company has three business segments including consumer, pharmaceutical and medical devices in which consumer is the market focused segment. The company has wide range of products under categories such as consumer health products, medical devices and pharmaceutical products in which consumer health products is the market focused category.

For instance,

  • In September 2017, Johnson & Johnson Services, Inc. presented new scientific data at European Academy of Dermatology and Venerology (EADV) Annual Meeting held in Geneva, Switzerland. During this meeting, the company has presented new finding in field of skin microbiome and treatment of androgenetic alopecia (hair loss) among others. The company also mentioned about its scientists which are continuously developing transformative solutions involving alopecia treatment (hair loss) among others. The company has also highlighted the data demonstrating the mechanism of action of minoxidil foam (rogaine). This initiative taken by the company created awareness among people regarding the hair loss treatment that the company is manufacturing.

The company has wide presence across Asia, Europe, America and Middle East and Africa. The company also has various subsidiary companies such as Janssen Pharmaceutica (Belgium), Neutrogena (U.S.), DePuy Synthes Companies (U.S.), Ethicon Inc. (U.S.), ALZA Corporation (U.S.) among others.

GlaxoSmithKline plc:

GlaxoSmithKline plc is headquartered in Ontario, Canada and was founded in 1715. The company is focused on bringing differentiated, high quality and needed healthcare products to as many people as possible with its three global businesses, scientific and technical know- how and talented people. The company operates its business through three business segments which are pharmaceuticals, vaccines and consumer healthcare in which pharmaceuticals is the market focused segment. The company has wide range of products under categories such as our prescription medicines, our vaccines, our consumer healthcare products, ViV Healthcare and stiefel- dermatology in which our prescription medicines is the market focused category.

For instance,

  • In August 2019, GlaxoSmithKline plc obtained positive views from Koreans regarding the usage of Avodart as a hair loss treatment. Avodart works by blocking the dihydrotestosterone (DHT) which is responsible for baldness which is highly observed among men. This positive outcome has helped the company to attain a lucrative growth in sales of alopecia treatment which has boosted the company’s overall revenue.

The company has presence across Africa, Asia & Middle East, Australasia, Europe, North America, South and Central America. The company has various subsidiaries such as 1506369 Alberta ULC (Canada), Action Potential Venture Capital Limited (England), Adechsa GmbH (Switzerland), Alenfarma – Especialidades Farmaceuticas, Limitada (Portugal), Allen & Hanburys Pharmaceutical Nigeria Limited (Nigeria) among others.

Taisho Pharmaceutical Holdings Co., Ltd.:

Taisho Pharmaceutical Holdings Co., Ltd. Is headquartered in Tokyo, Japan and was founded in 1912. The company is focused on manufacturing of OTC brands with a thought to improve patients’ health as its specialty. The company operates its business through two business segments which are self-medication operation group and prescription pharmaceutical operation group in which self-medication operation group is the market focused segment. The company has various products under categories that are lipovitan series, pabron series, RiUP series, counterpain, tempra, hapacol, dafalgan and efferalgan in which RiUP series is the market focused category.

For instance,

  • In May 2019, Taisho Pharmaceutical Holdings Co., Ltd. acquired the company Duoc Hau Giang Pharmaceutical JSC which is engaged in manufacturing and distribution of pharmaceutical products in Asian pharmaceutical market. This initiative hence strengthened the company’s presence in Asian market which allowed it to generate more revenue.

The company has presence in the Americas, Europe and Asia. The company also has various subsidiaries that are Taisho Pharmaceutical California Inc. (U.S.), Taisho Pharmaceutical (Taiwan) Co., Ltd (Taiwan), Grupo Imperial, S.A. de C.V. (Japan), Taisho Pharmaceutical (m) Sdn Bhd (Malaysia), PT Taisho Pharmaceutical Indonesia Tbk (Indonesia) among others.